IMUC Up 40% On Positive Feedback From European Medical Agency Lång

Beskrivning

⋅ 2 dec 2014 22:16

News: Phase 3 program given thumbs up for it's lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma

finance.yahoo.com/news/immunocellular-therapeutics-receives-positive-regulatory-110000104.html